Enanta Pharma (NASDAQ: ENTA) reported Q4 EPS of ($0.27), $0.06 better than the analyst estimate of ($0.33). Revenue for the quarter came in at $2.6 million versus the consensus estimate of $3.81 million.

For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.